Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome

References

• Abdalla H. I., Ah-Moye M., Brinsden P., Howe D. C., Okonofua F., Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertility & Sterility 1987; 48: 958–963
   PubMed Web of Science ®Google Scholar
• Aboulghar M., Evers J. H., Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome (Cochrane Review). The Cochrane Library. John Wiley & Sons, Ltd, ChichesterUK 2002
   Google Scholar
• Agrawal R., Conway G., Sladkevicius P., Tan S. L., Engmann L., Payne N., et al. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertility & Sterility 1998; 70: 651–658
   PubMed Web of Science ®Google Scholar
• Al-Inany H., Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Systematic Reviews 2006 2001, Issue 3, Art. no.: CD001750. DOI: 10.1002/14651858. CD001750.pub2
   Google Scholar
• Al-Inany H. G., Aboulghar M., Mansour R., Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. The Cochrane Database of Systematic Reviews 2005, Issue 2, Art. No.: CD003719
   PubMed Web of Science ®Google Scholar
• Asch R. H., Li H. P., Balmaceda J. P., Weckstein L. N., Stone S. C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction 1991; 10: 1395–1399
   Google Scholar
• Asch R., Ivery G., Goldsman M., Fredrick J. L., Stone S. C., Balmaceda J. P. The use of intravenous albumin in patients at high risk of ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 1015–1020
   PubMed Web of Science ®Google Scholar
• Balasch J., Fábregues F., Creus M., Puerto B., Peñarrubia J., Vanrell J. A. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Human Reproduction 2001; 16: 652–656
   PubMed Web of Science ®Google Scholar
• Bayram N., van Wely M., van der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database System Review 2001, Issue 2, Art. No.: CD002121
   PubMedGoogle Scholar
• Bellver J., Munoz E. A., Ballesteros A., Soares S. R., Bosch E., Simon C., et al. Intravenous albumin does not prevent moderate – severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Human Reproduction 2003; 18: 2283–2288
   PubMed Web of Science ®Google Scholar
• Benadiva C. A., Davis O., Kligman I., Moomjy M., Liu H. C., Rosenwaks Z. Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility & Sterility 1997; 67: 724–727
   PubMed Web of Science ®Google Scholar
• Ben-Rafael Z., Levy T., Schoemaker J. Pharmacokinetics of FSH: clinical significance. Fertility & Sterility 1995; 63: 689–700
   PubMed Web of Science ®Google Scholar
• Blankstein J., Shalev J., Saadon T. Ovarian hyperstimulation syndrome: prediction by numbers and size of preovulatory ovarian follicles. Fertility & Sterility 1987; 47: 597–602
   PubMed Web of Science ®Google Scholar
• Chang M. Y., Chiang C. H., Chiu T. H., Hsieh T. T., Soong Y. K. The antral follicle count predicts the outcome of pregnancy in a controlled ovarian hyperstimulation/intrauterine insemination program. Journal of Assisted Reproduction & Genetics 1998; 15: 12–17
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S., Hugues J. N. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Human Reproduction 2003; 18: 1626–1631
   PubMed Web of Science ®Google Scholar
• Chun S., Eisenhauer K., Minami S., Billig H., Perlas E., Hsueh A. Hormonal regulation of apoptosis in early astral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology 1996; 137: 1447–1456
   PubMed Web of Science ®Google Scholar
• Costello M. F., Chapman M., Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Human Reproduction 2006; 21: 1387–1399
   PubMed Web of Science ®Google Scholar
• Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility & Sterility 2002; 77: 711–714
   PubMed Web of Science ®Google Scholar
• Daya S., Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database System Review 2004, Issue 3, Art. No.: CD004830
   Google Scholar
• D'Angelo A., Amso N. N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction 2002; 17: 2787–2794
   PubMed Web of Science ®Google Scholar
• Delbaere A., Smits G., Olatunbosun O., Pierson R., Vassart G., Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. Human Reproduction 2004; 19: 486–489
   PubMed Web of Science ®Google Scholar
• Delvigne A., Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Human Reproduction 2001; 16: 2491–2495
   PubMed Web of Science ®Google Scholar
• Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 2002a; 8: 559–577
   PubMed Web of Science ®Google Scholar
• Delvigne A., Rozenberg S. A systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in in vitro fertilisation patients. Human Reproduction Update 2002b; 8: 291–296
   PubMed Web of Science ®Google Scholar
• Delvigne A., Demoulin A., Smitz J. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentre study; clinical and biological features. Human Reproduction 1993; 8: 1353–1360
   PubMed Web of Science ®Google Scholar
• Delvigne A., Vandromme J., Demeestre I., Leroy F. Unpredictable cases of complicated ovarian hyperstimulation in IVF. International Journal of Fertility 1997; 42: 268–270
   Google Scholar
• Dhont M., Van der Straeten F., De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertility & Sterility 1998; 70: 847–850
   PubMed Web of Science ®Google Scholar
• Doronzo G., Russo I., Mattiello L., Anfossi G., Bosia A., Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. European Journal of Clinical Investigation 2004; 34: 664–673
   PubMed Web of Science ®Google Scholar
• Egbase P. E., Makhseed M., Al Sharhan M., Grudzinskas J. G. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Human Reproduction 1997; 12: 2603–2606
   PubMed Web of Science ®Google Scholar
• Egbase P. E., Sharhan M. A., Grudzinskas J. G. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Human Reproduction 1999; 14: 1421–1425
   PubMed Web of Science ®Google Scholar
• Endo T., Honnma H., Hayashi T., Chida M., Yamazaki K., Kitajima Y., et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction 2002; 17: 2548–2551
   PubMed Web of Science ®Google Scholar
• Enskog A., Henriksson M., Unander M., Nilsson L., Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility & Sterility 1999; 71: 808–814
   PubMed Web of Science ®Google Scholar
• Farquhar C. M. The role of ovarian surgery in polycystic ovary syndrome. Best Practice & Research. Clinical Obstetrics & Gynaecology 2004; 18: 789–802
   PubMed Web of Science ®Google Scholar
• Ferraretti A. P., Gianaroli L., Magli C., Fortini D., Selman H. A., Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Human Reproduction 1999; 14: 1457–1460
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• García-Velasco J. A., Isaza V., Quea G., Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing?. Fertility & Sterility 2006; 85: 547–554
   PubMed Web of Science ®Google Scholar
• Gokmen O., Ugur M., Ekin M., Keles G., Turan C., Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. European Journal of Obstetrics, Gynecology & Reproductive Biology 2001; 96: 187–192
   PubMed Web of Science ®Google Scholar
• Graf M. A., Fischer R., Naether O. G., Baukloh V., Tafel T., Nuckel M. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Human Reproduction 1997; 12: 2599–2602
   PubMed Web of Science ®Google Scholar
• Homburg R., Howles C. M. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements. Human Reproduction Update 1999; 5: 493–499
   PubMed Web of Science ®Google Scholar
• Klemetti R., Sevón T., Gissler M., Hemm E. Complications of IVF and ovulation induction. Human Reproduction 2005; 20: 3293–3300
   PubMed Web of Science ®Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertility & Sterility 2004; 81: 1–5
   PubMed Web of Science ®Google Scholar
• Kolibianakis E. M., Schultze-Mosgau A., Schroer A., van Steirteghem A., Devroey P., Diedrich K., Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction 2005; 20: 2887–2892
   PubMed Web of Science ®Google Scholar
• Konig E., Bussen S., Sutterlin M., Steck T. Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Human Reproduction 1998; 13: 2421–2424
   PubMed Web of Science ®Google Scholar
• Lord J., Wilkin T. Metformin in polycystic ovary syndrome. Current Opinion in Obstetrics & Gynecology 2004; 16: 481–486
   PubMed Web of Science ®Google Scholar
• Ludwig M., Katalinic A., Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Archives of Gynecology & Obstetrics 2001; 265: 175–182
   PubMedGoogle Scholar
• MacDougall M. J., Tan S. L., Balen A., Jacobs H. S. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Human Reproduction 1993; 8: 233–237
   PubMed Web of Science ®Google Scholar
• Mansour R., Aboulghar M., Serour G., Amin Y., Abou-Setta A. M. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 2005; 20: 3167–3172
   PubMed Web of Science ®Google Scholar
• Marci R., Senn A., Dessole S., Chanson A., Loumaye E., Grandi P., Germond M. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertility & Sterility 2001; 75: 1131–1135
   PubMed Web of Science ®Google Scholar
• Mathur R. S., Joels L. A., Jenkins J. M. Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Acta Geneticae Medicae et Gemellologiae 1995; 44: 233–235
   PubMedGoogle Scholar
• Mathur R., Akande V., Keay S. D., Hunt L. P., Jenkins J. M. Distinction between early and late ovarian hyperstimulation syndrome. Fertility & Sterility 2000; 73: 901–907
   PubMed Web of Science ®Google Scholar
• Mathur R., Hayman G., Bansal A., Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertility & Sterility 2002; 78: 1154–1158
   PubMed Web of Science ®Google Scholar
• Mathur R., Evbuomwan I., Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstetrics & Gynaecology 2005; 15: 132–138
   Google Scholar
• Morris R. S., Paulson R. J., Sauer M. V., Lobo R. A. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Human Reproduction 1995; 10: 811–814
   PubMed Web of Science ®Google Scholar
• Navot D., Bergh P. A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility & Sterility 1992; 58: 249–261
   PubMed Web of Science ®Google Scholar
• Nugent D., Vandekerckhove P., Hughes E., Arnot M., Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. The Cochrane Database of Systematic Reviews 2000, Issue 3
   PubMedGoogle Scholar
• Orvieto R. Can we eliminate severe ovarian hyperstimulation syndrome?. Human Reproduction 2005; 20: 320–322
   PubMed Web of Science ®Google Scholar
• Palomba S., Falbo A., Orio F., Jr., Manguso F., Russo T., Tolino A., et al. A randomized controlled trial evaluating metformin pretreatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Human Reproduction 2005; 20: 2879–2886
   PubMed Web of Science ®Google Scholar
• Pau E., Alonso-Muriel I., Gómez R., Novella E., Ruiz A., García-Velasco J. A., et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Human Reproduction 2006; 21: 1453–1460
   PubMed Web of Science ®Google Scholar
• Reljic M., Vlaisavljevic V., Gavric V., Kovacic B. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome. Journal of Reproductive Medicine 1999; 44: 713–718
   PubMed Web of Science ®Google Scholar
• Rimington M. R., Walker S. M., Shaw R. W. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Human Reproduction 1997; 12: 1443–1447
   PubMed Web of Science ®Google Scholar
• Schenker J. G. Prevention and treatment of ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 653–659
   PubMedGoogle Scholar
• Schroder A. K., Schopper B., Al-Hasani S., Diedrich K., Ludwig M. Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology & Reproductive Biology 2003; 110: 186–189
   PubMed Web of Science ®Google Scholar
• Schwärzler P., Abendstein B. J., Klingler A., Kreuzer E., Rjosk H. K. Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression – a prospective randomized study. Human Fertility 2003; 6: 125–129
   Google Scholar
• Shaker A. G., Zosmer A., Dean N., Bekir S. J., Jacobs H. S., Tan S. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertility & Sterility 1996; 65: 992–996
   PubMed Web of Science ®Google Scholar
• Tang T., Glanville J., Orsi N., Barth J. H., Balen A. H. The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction 2006; 21: 1416–1425
   PubMed Web of Science ®Google Scholar
• Tarlatzis B. C., Fauser B. C., Kolibianakis E. M., Diedrich K., Devroey P., (Brussels GnRH Antagonist Consensus Workshop Group). GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update Advance Access 27 March, 2006
   Google Scholar
• Tortoriello D. V., McGovern P. G., Colon J. M., Skurnick J. H., Lipetz K., Santoro N. ‘Coasting’ does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility & Sterility 1998; 69: 454–460
   PubMed Web of Science ®Google Scholar
• Tozer A. J., Al-Shawaf T., Zosmer A., Hussain S., Wilson C., Lower A. M., Grudzinskas J. G. Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Human Reproduction 2001; 16: 91–95
   PubMed Web of Science ®Google Scholar
• Tozer A., Iles R., Iammarrone E., Guillott C., Al-Shawaf T., Grudzinskas J. The effects of coasting on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Human Reproduction 2004; 19: 522–528
   PubMed Web of Science ®Google Scholar
• van der Meer S., Gerris J., Joostens M., Tas B. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 1628–1631
   PubMed Web of Science ®Google Scholar
• van der Meer M., Hompes P. G., De Boer J. A., Schats R., Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 1998; 83: 423–426
   PubMed Web of Science ®Google Scholar
• Zhu W. J., Li X. M., Chen X. M., Zhang L. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization. European Journal of Obstetrics, Gynecology & Reproductive Biology 2005; 122: 79–84
   PubMed Web of Science ®Google Scholar